Related Experiment Video
Updated: Oct 25, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity
Lu-Jie Liu1, Yu-Rong Kang1, Yan-Feng Xiao2
1Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xiwu Road, Xi'an 710061, China.
Background:
Obesity is a common disease among children, often accompanied by a lot of metabolic disease. Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of obesity among children and adolescents. Asprosin has been identified as a new adipokine that is closely associated with hepatic glucose metabolism. However, few data on asprosin in obese children with NAFLD are available. The present study focuses on the relationship between serum asprosin level and NAFLD in children with obesity.
Methods:
A total of 110 subjects (71 boys and 39 girls aged 6-18 years) were recruited from the Second Affiliated Hospital of Xi'an Jiaotong University: 36 obese children with NAFLD, 39 obese children without NAFLD and 35 lean controls. Anthropometric parameters and biochemical data were measured, and the concentrations of asprosin were detected by ELISA.
Results:
The levels of serum asprosin were significantly higher in obese children, particularly those with NAFLD and were positively correlated with body mass index, waist to height ratio, fasting blood glucose, alanine aminotransferase and tumor necrosis factor-alpha. Furthermore, asprosin was independently associated with NAFLD in binary logistic regression analysis.
Conclusion:
Serum asprosin levels were elevated in obese children, especially in those with NAFLD, and were involved in the pathogenesis of NAFLD in children with obesity.
More Related Videos
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Obesity
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

